CTIS2022-500100-21-01招募中1 期
Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841)
Oslo University Hospital Hf0 个研究点目标入组 80 人开始时间: 2022年10月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Written informed consent according to ICH-GCP guidelines, Age = 18 years, Follicular lymphoma grade 1-3a with a current relapse or progression within 24 months of starting 1st line treatment or refractory to 1st line treatment (POD24), more specifically: a. Documented current relapse or progression of FL within 24 months of starting first line treatment containing a monospecific anti-CD20 antibody (such as rituximab or obinutuzumab with or without chemotherapy, small molecular inhibitors or immunomodulating agents such as lenalidomide). b. Alternatively, current lack of response/refractoriness to first line treatment, i.e., no objective response or documented progression within 6 months following at least four cycles of monotherapy with a monospecific anti-CD20 antibody (such as rituximab 375mg/m2 iv or 1400 mg SC or equal) or following at least three cycles of a monospecific anti CD20 antibody combined with chemotherapy, small molecular inhibitors or immunomodulating agents such as lenalidomide. c. Received one prior treatment line of systemic therapy. d. If the POD24 event was diagnosed more than three months ago, then study inclusion has been clarified with the coordinating investigator. e. Patients may have received localized radiotherapy previously. Patients may have received localized radiotherapy previously. If the radiotherapy was recent, the patient must have at least one progressive and measurable lesion outside the radiation field., At least one two-dimensionally measurable lesion with a longest diameter >15mm., WHO performance status 0-2. Patients with reduced WHO performance status (> 2) can be considered if reduction in performance is caused by the lymphoma as determined by the investigator.
排除标准
- •Received 2 or more previous treatment lines., Impaired liver function not caused by lymphoma, defined as serum total bilirubin = 1.5 x ULN (unless elevated due to Gilbert’s syndrome) or serum ALT and AST ? 3 x ULN, Impaired renal function not caused by lymphoma, defined as calculated creatinine clearance <= 40 ml/minute, Grade 3b FL., Other major organ dysfunction not caused by lymphoma, Known history of drug induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, primary biliary cirrhosis, on-going extra-hepatic obstruction caused by cholelithiasis, cirrhosis of the liver or portal hypertension., HIV positivity: Subjects that are on HIV-treatment with undetectable HIV-RNA and CD4-counts above 200 will be eligible., Women of reproductive potential not agreeing to use an acceptable method of birth control during treatment and for three months after completion of treatment., Hepatitis B (HBV) or hepatitis C (HCV) infection: Subjects with a previous hepatitis B infection will be eligible if they are negative for HBV-DNA; these subjects must be given prophylactic antiviral therapy. Subjects with a previous HCV infection will be eligible if they are negative for HCV-RNA., Known or suspected chronic active Epstein-Barr virus (EBV) infection., Received systemic immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within two weeks prior to the first dose of mosunetuzumab., Other current severe medical problems or expected survival of less than approximately five years for non-lymphoma reasons., Administration of live vaccines within four weeks of the first dose of mosunetuzumab or anticipation that live vaccine will be required during the study., History of severe allergic or anaphylactic reactions to chimeric, human, or humanized antibodies, or fusion proteins., Known or suspected hemophagocytic syndrome., Prior allogeneic hematopoietic stem cell transplant., Active severe infection., Current or previous other malignancy within three years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other non-invasive or indolent malignancy without sponsor approval., CD20-negative lymphoma, Psychiatric disorder or dementia which make the patient unable to give an informed consent and/or adhere to the schedule., Pregnancy or breast-feeding., CNS involvement (current or previous), Impaired bone marrow function (neutrophils < 1.0 x 10^9/L or platelets < 50 x 10^9/L) unless due to lymphoma involvement, Severe cardiac disease: impaired cardiac function (NYHA class III or IV), myocardial infarction within the last 6 months, unstable arrythmias and/or unstable angina pectoris.
研究者
相似试验
进行中（未招募）
1 期
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/ Unfit Participants With Previously Untreated Diffuse Large B-Cell LymphomaPreviously untreated Diffuse Large B-Cell Lymphoma (DLBCL)MedDRA version: 21.0Level: PTClassification code: 10012821Term: Diffuse large B-cell lymphoma recurrent Class: 100000004864CTIS2023-507498-16-00F. Hoffmann-La Roche AG179
招募中
2 期
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)NCT06594939Medical College of Wisconsin31
已完成
1 期
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin LymphomaB-cell Non-Hodgkin LymphomaNCT03677141Hoffmann-La Roche117
进行中（未招募）
1 期
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular LymphomaFollicular LymphomaNCT04246086Hoffmann-La Roche237
招募中
1 期
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell LymphomaDiffuse Large B-Cell LymphomaHigh Grade B-Cell LymphomaNCT06249191OHSU Knight Cancer Institute40